Tyra Financial Statements From 2010 to 2025

TYRA Stock  USD 11.15  0.05  0.45%   
Tyra Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Tyra Biosciences' valuation are provided below:
Market Capitalization
595.6 M
Earnings Share
(1.63)
We have found one hundred twenty available fundamental trend indicators for Tyra Biosciences, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Tyra Biosciences current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Enterprise Value is expected to grow to about 670.6 M, whereas Market Cap is forecasted to decline to about 452.5 M.
Check Tyra Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tyra Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 18.6 M, Depreciation And Amortization of 545 K or Interest Expense of 357.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.43. Tyra financial statements analysis is a perfect complement when working with Tyra Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Tyra Stock
Check out the analysis of Tyra Biosciences Correlation against competitors.
For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.

Tyra Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets216.1 M363.6 M87.5 M
Slightly volatile
Short and Long Term Debt Total6.5 M6.2 M1.6 M
Slightly volatile
Other Current Liabilities14.3 M13.6 M5.8 M
Slightly volatile
Total Current Liabilities8.5 M14.6 M6.3 M
Slightly volatile
Property Plant And Equipment Net4.1 M7.7 M1.8 M
Slightly volatile
Current Deferred Revenue291.2 K327.6 K357.2 K
Slightly volatile
Accounts Payable560.5 K590 K718.2 K
Slightly volatile
Cash131.8 M92 M53.2 M
Slightly volatile
Non Current Assets Total16.9 M16.1 MM
Slightly volatile
Non Currrent Assets Other8.8 M8.4 M1.8 M
Slightly volatile
Cash And Short Term Investments204.2 M341.4 M82.4 M
Slightly volatile
Common Stock Shares Outstanding49.2 M57.2 M43.8 M
Slightly volatile
Non Current Liabilities Total5.9 M5.8 M3.2 M
Slightly volatile
Capital Lease Obligations6.5 M6.2 M1.6 M
Slightly volatile
Other Current Assets4.4 MM1.8 M
Slightly volatile
Total Liabilities16.5 M20.4 M9.6 M
Slightly volatile
Deferred Long Term Liabilities85.6 K96.3 K105 K
Slightly volatile
Property Plant And Equipment Gross4.6 MMM
Slightly volatile
Total Current Assets208.2 M347.5 M84.1 M
Slightly volatile
Short Term Debt303.8 K412 K200.7 K
Slightly volatile
Property Plant Equipment782.6 K1.2 M526.8 K
Slightly volatile
Other Liabilities247.9 K194.3 K168 K
Slightly volatile
Other Stockholder Equity432.3 M593.7 M150.1 M
Slightly volatile
Non Current Liabilities Other2.9 KK349.4 K
Pretty Stable
Common Stock Total Equity3.2 K3.6 K3.9 K
Slightly volatile
Capital Surpluse382.6 M406.5 M350.1 M
Slightly volatile
Common Stock4.7 KK4.1 K
Slightly volatile
Net Receivables560 K630 K686.9 K
Slightly volatile

Tyra Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization545 K519 K123.7 K
Slightly volatile
Interest Expense357.4 K340.4 K90.1 K
Slightly volatile
Selling General Administrative12.2 M24.1 M5.7 M
Slightly volatile
Other Operating Expenses96.5 M91.9 M24.6 M
Slightly volatile
Research Development84.1 M80.1 M19.7 M
Slightly volatile
Cost Of Revenue545 K519 K123.7 K
Slightly volatile
Total Operating Expenses109.4 M104.2 M26.2 M
Slightly volatile
Reconciled Depreciation545 K519 K123.7 K
Slightly volatile
Interest Income8.9 M17.7 M2.6 M
Slightly volatile
Selling And Marketing Expenses13.9 M15.7 M17.1 M
Slightly volatile

Tyra Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow115.8 M59 M48.2 M
Slightly volatile
Other Cashflows From Financing Activities2.4 M2.6 M10.1 M
Pretty Stable
Depreciation545 K519 K123.7 K
Slightly volatile
Capital Expenditures547.4 K664 K232.1 K
Slightly volatile
Total Cash From Financing Activities212.2 M202.1 M47 M
Slightly volatile
End Period Cash Flow132.4 M93 M53.5 M
Slightly volatile
Change To Netincome12.8 M12.2 M3.7 M
Slightly volatile
Change To Liabilities1.5 M2.7 MM
Slightly volatile
Other Cashflows From Investing Activities12.814.415.7
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation1.221.27942.6831
Very volatile
Payables Turnover0.920.87970.1677
Slightly volatile
Cash Per Share3.255.96741.7284
Slightly volatile
Days Payables Outstanding39441510.2 K
Slightly volatile
Income Quality0.640.80680.7035
Slightly volatile
Current Ratio23.3423.808612.4151
Slightly volatile
Capex Per Share0.00890.01160.005
Slightly volatile
Interest Debt Per Share0.110.10870.0328
Slightly volatile
Debt To Assets0.01630.01710.3048
Slightly volatile
Days Of Payables Outstanding39441510.2 K
Slightly volatile
Ebt Per Ebit1.090.83011.1718
Slightly volatile
Effective Tax Rate0.06150.05860.0172
Slightly volatile
Quick Ratio23.3423.808612.4151
Slightly volatile
Net Income Per E B T1.080.93491.0003
Pretty Stable
Cash Ratio5.996.30169.5069
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00951.0188
Slightly volatile
Debt Ratio0.01630.01710.3048
Slightly volatile

Tyra Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap452.5 M715.8 M579.9 M
Very volatile
Enterprise Value670.6 M638.6 M342.1 M
Slightly volatile

Tyra Fundamental Market Drivers

Cash And Short Term Investments341.4 M

Tyra Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tyra Biosciences Financial Statements

Tyra Biosciences stakeholders use historical fundamental indicators, such as Tyra Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Tyra Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Tyra Biosciences' assets and liabilities are reflected in the revenues and expenses on Tyra Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Tyra Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue327.6 K291.2 K
Cost Of Revenue519 K545 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Tyra Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tyra Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tyra Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tyra Biosciences Stock:
Check out the analysis of Tyra Biosciences Correlation against competitors.
For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tyra Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.63)
Return On Assets
(0.19)
Return On Equity
(0.27)
The market value of Tyra Biosciences is measured differently than its book value, which is the value of Tyra that is recorded on the company's balance sheet. Investors also form their own opinion of Tyra Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Tyra Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tyra Biosciences' market value can be influenced by many factors that don't directly affect Tyra Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tyra Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.